Opella, a global leader in self-care, enters a transformative phase as Sanofi finalizes the sale of a 50 percent controlling stake to Clayton, Dubilier & Rice (CD\&R). Sanofi retains a significant 48.2 percent shareholding, with Bpifrance holding 1.8 percent.
Beyond the sale of a significant share block, the sale is a strategic shift toward agility and growth for Opella.
As the third-largest player in the EURO190 billion Over-The-Counter and Vitamins, Minerals & Supplements market, Opella is positioned to lead a fast-changing sector shaped by aging populations, digital health, and rising self-care demand.
Headquartered in France with global reach, Opella’s 100 trusted brands—including Erceflora, Buscopan, and Dulcolax—serve over half a billion consumers. With 11,000 employees, 13 manufacturing sites, and four science centers, the company is grounded in innovation, consumer insight, and sustainability.
Its mission, “Health in Your Hands,” reflects a commitment to simplifying self-care and expanding access. With new backing, Opella plans to strengthen key brands, expand in priority markets, and pursue smart growth through acquisitions and prescription-to-OTC switches.
-0-
